This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Antares Pharma Welcomes Robert P. Roche Jr. To Board Of Directors

Antares Pharma, Inc. (NASDAQ: ATRS) today announced the election of Robert P. Roche Jr. to the Company’s Board of Directors.

Mr. Roche has served as principal of Robert Roche Associates LLC, a consulting firm providing guidance to the pharmaceutical and healthcare industries since February 2010. From January 1995 through February of 2010, Mr. Roche led commercial operations at Cephalon, Inc., a global biopharmaceutical company. Prior to his retirement from Cephalon, Mr. Roche held the position of Executive Vice President, Worldwide Pharmaceutical Operations, in which capacity he oversaw several successful new product launches.

Leonard S. Jacob, M.D., Ph.D., Chairman of the Board of Antares Pharma, stated, “The addition of Bob Roche to our Board is welcomed and timely. His background and success in commercial operations and product launches will serve to complement the experienced sales and marketing team that Antares has assembled. Subject to FDA approval, the Company plans to launch OTREXUP™ for the treatment of rheumatoid arthritis early next year.”

“I am excited to be joining the Board of Antares Pharma at this point in the Company’s growth,” said Robert P. Roche Jr. “The Company has developed a comprehensive commercialization plan for OTREXUP™ which I am confident will result in a well-coordinated launch early next year. The launch plan will also serve as a template for other drug-device combination products in their pipeline, such as QS T for Testosterone Replacement Therapy,” added Mr. Roche.

Mr. Roche was elected unanimously by the Company’s Board of Directors at the recommendation of the Nomination and Governance Committee. Before joining Cephalon, Mr. Roche served as Director and Vice President, Worldwide Strategic Product Development for SmithKline Beecham’s central nervous system and gastrointestinal products business. Prior to that, he held senior marketing positions in Canada and Spain and had product planning responsibilities for SmithKline in Latin America. Mr. Roche began his pharmaceutical career in 1982 with SmithKline & French as a U.S. Pharmaceutical sales representative. He is a graduate of Colgate University and earned an MBA from the Wharton School at the University of Pennsylvania.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs